Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,073 total articles

Constellation Brands to Report First Quarter Fiscal 2027  Financial Results on June 30, 2026 After Market Close and Host Conference Call on July 1, 2026 at 8:00 am ET

Constellation Brands to Report First Quarter Fiscal 2027 Financial Results on June 30, 2026 After Market Close and Host Conference Call on July 1, 2026 at 8:00 am ET

Constellation Brands, a leading beverage alcohol producer and marketer, will report its Q1 fiscal 2027 financial results on June 30, 2026, after market close, followed by a conference call on July 1. The company plans to discuss its financial performance, strategic initiatives, and outlook during the call, highlighting its diverse portfolio of beer…

Hubbell Incorporated Prices $1.9 Billion Senior Notes Offering

Hubbell Incorporated Prices $1.9 Billion Senior Notes Offering

Hubbell Incorporated announced the successful pricing of a $1.9 billion senior notes offering consisting of fixed-rate notes due in 2031, 2033, and 2036. Proceeds will be used to finance the proposed acquisition of NSI Electrical Buyer, repay NSI's debt, cover transaction costs, and for general corporate purposes. The offering is expected to close …

Alvotech to present at upcoming investor conferences in June

Alvotech to present at upcoming investor conferences in June

Alvotech, a biotechnology company specializing in biosimilar medicines, announced that its Founder and Executive Chairman Robert Wessman, along with Chief Strategy Officer Dr. Balaji V. Prasad, will participate in investor conferences in June 2026 including Jefferies, Goldman Sachs, and UBS events. The presentations will be webcast live and recorde…

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

Tenaya Therapeutics will present new interim data from cohorts 1 and 2 of the Phase 1b/2 MyPEAK-1 trial evaluating TN-201, a gene therapy aimed at treating adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM). The company highlights TN-201’s potential to address the genetic root cause of this severe heart condition through a single intra…

Neuronetics Appoints Robert Greene as Senior Vice President Sales

Neuronetics Appoints Robert Greene as Senior Vice President Sales

Neuronetics, Inc., a US-based medical technology company specializing in neurohealth products, announced the appointment of Robert Greene as Senior Vice President Sales effective June 1, 2026. Greene brings extensive experience in healthcare sales and will receive restricted stock units as part of his compensation. The company focuses on NeuroStar …

ATN International, Inc. Completes Initial Closing on the Sale of its Towers and Updates 2026 Outlook

ATN International, Inc. Completes Initial Closing on the Sale of its Towers and Updates 2026 Outlook

ATN International, Inc. announced the initial closing of its $268 million sale of Southwestern U.S. towers to Everest Infrastructure Partners. Proceeds will strengthen liquidity and reduce debt. The sale is expected to lower 2026 revenue, operating income, and Adjusted EBITDA, causing the firm to revise its 2026 Adjusted EBITDA guidance downward to…

Xos Launches the 2.5MWh Power Hub, Delivering Grid-Independent Energy Storage to Data Centers in Days, Not Years

Xos Launches the 2.5MWh Power Hub, Delivering Grid-Independent Energy Storage to Data Centers in Days, Not Years

Xos, Inc. has introduced the 2.5MWh Power Hub series, a factory-integrated, rapidly deployable energy storage and hybrid power system designed to deliver megawatt-scale power within days, bypassing traditional 3 to 7 year US grid interconnection delays. Built on a proven platform with over 250 MWh deployed across North America, the Power Hub target…

Crescent Biopharma to Present at June Investor Conferences

Crescent Biopharma to Present at June Investor Conferences

Crescent Biopharma, a clinical-stage biotechnology company focused on cancer therapies, announced that its management will present at the 2026 Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference in June 2026. The presentations will be webcast live and replayed on the company's investor website.

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities

Crinetics Pharmaceuticals, a US-based biotech firm specializing in endocrine disorders, has launched 'Everyday Advocacy,' a patient-centered program providing education, support, and tools to empower individuals with endocrine and related conditions. Developed in collaboration with leading patient organizations, the initiative aims to improve patie…

Netskope Joins Anthropic’s Project Glasswing

Netskope Joins Anthropic’s Project Glasswing

Netskope (NASDAQ: NTSK) has joined Anthropic's Project Glasswing, leveraging Anthropic’s advanced AI model, Mythos Preview, to detect vulnerabilities in code swiftly and at scale. This collaboration enhances Netskope's ability to provide real-time governance and security across AI applications and enterprise traffic, addressing critical gaps in AI …

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

Vaxcyte, Inc. announced the dosing of the first participant in its Phase 1 clinical trial evaluating VAX-A1, a novel vaccine candidate designed to prevent diseases caused by Group A Streptococcus (Group A Strep). This dose-escalation study aims primarily to assess safety and tolerability, with secondary evaluation of immune response in healthy adul…

Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution

Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution

Cue Biopharma announced key changes to its board of directors as part of its strategic evolution toward becoming a late-stage clinical company. Four independent directors resigned, and the company appointed Daniel Camardo, an experienced CEO with commercial launch success, and Viola Meehan, a seasoned CFO with extensive finance and governance exper…

BriaCell Therapeutics Announces Closing of Offering

BriaCell Therapeutics Announces Closing of Offering

BriaCell Therapeutics Corp., a clinical-stage biotechnology company focused on cancer immunotherapies, announced the closing of a best-efforts offering of approximately 1.45 million common shares at $3.25 per share, raising gross proceeds of about $4.7 million. The funds will be used for working capital, general corporate purposes, and advancing bu…